Latest News

Coronavirus: One vaccine dose enough to cut transmission risk by half, AstraZeneca/EU legal challeng

0

In Wednesday’s UK coronavirus news, a new study by Public Health England (PHE) has shown that one dose of a vaccine reduces household transmission by up to half.

Researchers studied 57,000 contacts from 24,000 households where a person who had received the jab contracted the virus.

READ: AstraZeneca sued by EU Commission over COVID-19 vaccine deliveries

They were between 38% and 49% less likely to pass the virus on to people living with them that had not been vaccinated yet.

Subjects had received either the AstraZeneca PLC (LON:AZN) or the BioNTech/Pfizer jabs.

“Vaccines are vital in helping us return to a normal way of life. Not only do vaccines reduce the severity of illness and prevent hundreds of deaths every day, we now see they also have an additional impact on reducing the chance of passing COVID-19 on to others,” said Dr Mary Ramsay, head of immunisation at PHE.

“While these findings are very encouraging, even if you have been vaccinated, it is really important that you continue to act like you have the virus, practise good hand hygiene and follow social distancing guidance.”

Legal challenge begins

Meanwhile, court proceedings in the AstraZeneca/EU case have begun in Brussels on Wednesday.

The EU Commission has sued the pharma giant over COVID-19 vaccine deliveries, after it cut supplies below the levels indicated by initial contracts.

“AstraZeneca has fully complied with the Advance Purchase Agreement with the European Commission and will strongly defend itself in court. We believe any litigation is without merit and we welcome this opportunity to resolve this dispute as soon as possible,” it said in a statement earlier this week.

Shares in the FTSE 100 group were flat at 7,563p in the late morning.

Seeing Machines hails increasing US momentum for mandatory driver monitoring technology

Previous article

FTSE 100 edges higher, while ITV gains on advertising growth hopes

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News